{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:40:32Z","timestamp":1790743232613,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD) is an X-linked condition caused by variants in the <jats:italic>GLA<\/jats:italic> gene. Since females have two X chromosomes, they were historically thought to be carriers. Although increased knowledge has shown that females often develop the disease, data from Spain and other countries reported that females were undertreated. The aim of this study was to provide a wider and more recent description of the disease characteristics and associated management of females with a <jats:italic>GLA<\/jats:italic> variant in a Spanish cohort.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ninety-seven females from 12 hospitals were included in this retrospective study. Mean age was 50.1\u2009\u00b1\u200917.2\u00a0years. Median follow-up time from <jats:italic>GLA<\/jats:italic> variant identification was 36.1\u00a0months, and most (70.1%) were identified through family screening. Variants associated with classic\/non-classic phenotypes were similarly distributed (40.2%\/53.6%). Missense variants were the most prevalent (n\u2009=\u200984, 86.6%). In the overall group, 70.4% had major organ involvement (i.e., cardiac, renal, cerebrovascular, peripheral nervous system or gastrointestinal), and 47.3% also had typical Fabry signs (angiokeratoma, cornea verticillata or increased plasma lyso-Gb3). Cardiac involvement was the most prevalent (49.5%) and the main reason for treatment initiation. A total of 33 (34%) patients received disease-specific therapy, 55% of whom were diagnosed by family screening. Females carrying variants associated with a classic phenotype had higher frequencies of clinical manifestations (92.3%) and were predominant in the treated subgroup (69.7%). Despite this, there were 34 untreated females (56.7% of total untreated), with both phenotypes represented, who had major organ involvement, with 27 of cardiac, renal or cerebrovascular nature. Age or comorbidities in this subgroup were comparable to the treated subgroup (<jats:italic>P<\/jats:italic>\u2009=\u20090.8 and <jats:italic>P<\/jats:italic>\u2009=\u20090.8, respectively).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Efforts have been made in recent years to diagnose and treat timely Fabry females in Spain. A high percentage of females with pathogenic variants, regardless of their associated phenotype, will likely develop disease. A proportion of females with severe disease in this cohort received specific treatment. Still a significant number of females, even with same profile as the treated ones, who may be eligible for treatment according to European recommendations, remained untreated. Reasons for this merit further investigation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02599-w","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:04:41Z","timestamp":1673280281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-3029","authenticated-orcid":false,"given":"Rosario","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Ripoll-Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"L\u00f3pez-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"de Juan-Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ram\u00f3n","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Aurora","family":"Ruz-Zafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Vicente","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Aguinaga-Barrilero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"1","key":"2599_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):30.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2599_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","volume":"82","author":"T L\u00fccke","year":"2004","unstructured":"L\u00fccke T, H\u00f6ppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004;82(1):93\u20137.","journal-title":"Mol Genet Metab"},{"key":"2599_CR3","unstructured":"Mehta A., Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2022 Jan 27]. In: Adam MP ED, Mirzaa GM, et al., editor. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/"},{"issue":"20","key":"2599_CR4","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","volume":"24","author":"MD Sanchez-Ni\u00f1o","year":"2015","unstructured":"Sanchez-Ni\u00f1o MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. Hum Mol Genet. 2015;24(20):5720\u201332.","journal-title":"Hum Mol Genet"},{"key":"2599_CR5","unstructured":"Desnick RJ IY, Eng CM. Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C BA, editor. The online metabolic & molecular bases of inherited diseases: McGraw-Hill; 2001. p. 3733\u201374. https:\/\/ommbid.mhmedical.com\/content.aspx?sectionid=225546984&bookid=2709"},{"issue":"3","key":"2599_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"10","key":"2599_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30(10):1397\u2013405.","journal-title":"Hum Mutat"},{"issue":"1","key":"2599_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"9813","key":"2599_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jes\u00fas VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335\u201341.","journal-title":"Lancet"},{"key":"2599_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn screening for lysosomal storage disorders in illinois: the initial 15-month experience. J Pediatr. 2017;190:130\u20135.","journal-title":"J Pediatr"},{"issue":"7","key":"2599_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamapediatrics.2018.0263","volume":"172","author":"PV Hopkins","year":"2018","unstructured":"Hopkins PV, Klug T, Vermette L, Raburn-Miller J, Kiesling J, Rogers S. Incidence of 4 lysosomal storage disorders from 4 years of newborn screening. JAMA Pediatr. 2018;172(7):696\u20137.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"2599_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","volume":"176","author":"C Colon","year":"2017","unstructured":"Colon C, Ortolano S, Melcon-Crespo C, Alvarez JV, Lopez-Suarez OE, Couce ML, et al. Newborn screening for Fabry disease in the north-west of Spain. Eur J Pediatr. 2017;176(8):1075\u201381.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"2599_CR13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1159\/000494678","volume":"43","author":"CJ Lin","year":"2018","unstructured":"Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, et al. Results of fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a Northern Taiwan Medical Center. Kidney Blood Press Res. 2018;43(5):1636\u201345.","journal-title":"Kidney Blood Press Res"},{"key":"2599_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2599_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2599_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236\u201342.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2599_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91(2):284\u201393.","journal-title":"Kidney Int"},{"issue":"11","key":"2599_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"issue":"7","key":"2599_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1023\/A:1012993305223","volume":"24","author":"C Whybra","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001;24(7):715\u201324.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2599_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112\u201328.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2599_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2599_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"key":"2599_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2599_CR24","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2599_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-K\u00fchl S, Sommer C, et al. Multicenter Female Fabry Study (MFFS)\u2014clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2599_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jmd2.12071","volume":"49","author":"AM Martins","year":"2019","unstructured":"Martins AM, Cabrera G, Molt F, Su\u00e1rez-Obando F, Vald\u00e9s RA, Varas C, et al. The clinical profiles of female patients with Fabry disease in Latin America: a Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status. JIMD Rep. 2019;49(1):107\u201317.","journal-title":"JIMD Rep"},{"issue":"12","key":"2599_CR27","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/ijms17121965","volume":"17","author":"M Barba-Romero","year":"2016","unstructured":"Barba-Romero M, Pintos-Morell G. Gender differences in the application of Spanish criteria for initiation of enzyme replacement therapy for Fabry disease in the Fabry Outcome Survey. Int J Mol Sci. 2016;17(12):1965.","journal-title":"Int J Mol Sci"},{"key":"2599_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","volume":"16","author":"I Vardarli","year":"2020","unstructured":"Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag. 2020;16:551\u20138.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"2599_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.medcli.2018.10.039","volume":"153","author":"MA Barba-Romero","year":"2019","unstructured":"Barba-Romero MA, Serena J, Puig JM, Valverde CV, Climent V, Herrero JA, et al. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Med Clin (Barc). 2019;153(2):47\u201355.","journal-title":"Med Clin (Barc)"},{"key":"2599_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.nefroe.2022.01.003","volume":"41","author":"M Goicoechea","year":"2021","unstructured":"Goicoechea M, Gomez-Preciado F, Benito S, Torras J, Torra R, Huerta A, et al. Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. Nefrologia (Engl Ed). 2021;41:652\u201360.","journal-title":"Nefrologia (Engl Ed)"},{"issue":"8","key":"2599_CR31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","volume":"57","author":"DP Germain","year":"2020","unstructured":"Germain DP, Oliveira JP, Bichet DG, Yoo HW, Hopkin RJ, Lemay R, et al. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. J Med Genet. 2020;57(8):542\u201351.","journal-title":"J Med Genet"},{"key":"2599_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110779","volume":"131","author":"S Kant","year":"2020","unstructured":"Kant S, Atta MG. Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother. 2020;131: 110779.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2599_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139.","journal-title":"J Med Genet"},{"issue":"5","key":"2599_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","volume":"22","author":"DA Laney","year":"2013","unstructured":"Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013;22(5):555\u201364.","journal-title":"J Genet Couns"},{"issue":"8 Pt 2","key":"2599_CR35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging. 2019;12(8 Pt 2):1673\u201383.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2599_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","volume":"126","author":"F Weidemann","year":"2019","unstructured":"Weidemann F, Beer M, Kralewski M, Siwy J, Kampmann C. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Mol Genet Metab. 2019;126(2):169\u201382.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2599_CR37","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ymgme.2016.11.082","volume":"120","author":"RJ Desnick","year":"2017","unstructured":"Desnick RJ, Chen R, Srinivasan R, Doheny DO, Bishop D. The Fabry disease genotype-phenotype database (dbFGP): an international expert consortium. Mol Genet Metab. 2017;120(1):S41\u20132.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2599_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/jhg.2011.31","volume":"56","author":"S Saito","year":"2011","unstructured":"Saito S, Ohno K, Sakuraba H. Fabry-database.org: database of the clinical phenotypes, genotypes and mutant \u03b1-galactosidase A structures in Fabry disease. J Hum Genet. 2011;56(6):467\u20138.","journal-title":"J Hum Genet"},{"issue":"4","key":"2599_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"key":"2599_CR40","doi-asserted-by":"crossref","unstructured":"Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl (2011). 2013;3(1):63\u201372.","DOI":"10.1038\/kisup.2012.65"},{"key":"2599_CR41","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12883-015-0513-z","volume":"15","author":"L Fancellu","year":"2015","unstructured":"Fancellu L, Borsini W, Romani I, Pirisi A, Deiana GA, Sechi E, et al. Exploratory screening for Fabry\u2019s disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurol. 2015;15:256.","journal-title":"BMC Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:08:19Z","timestamp":1673280499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02599-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of all participating centres (Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain, Hospital Serran\u00eda de Ronda, M\u00e1laga, Spain, Fundaci\u00f3n Puigvert, Barcelona, Spain, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain, Hospital Cl\u00ednico Universitario de Santiago CHUS, A Coru\u00f1a, Spain, Hospital Universitario Son Ll\u00e0tzer, Illes Balears, Spain, Hospital Universitari Son Espases, Illes Balears, Spain, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia, Spain, Hospital General Universitario de Alicante, Alicante, Spain, Hospital General Universitario de Elda, Alicante, Spain and Hospital General Universitario de Elche, Alicante, Spain). Written informed consent was obtained from all alive patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RS has participated in advisory boards, clinical trials, and sponsored registries, and has received honoraria for lectures, attending meetings and\/or travel, from Shire, Takeda, Amicus Therapeutics, Sanofi Genzyme, Eusa Pharma and Bayer. TRV has received honoraria for advisory roles from Amicus Therapeutics. MLM has received honoraria for lectures or educational events from Amicus Therapeutics, Sanofi Genzyme and Takeda-Shire, and has participated in advisory boards of Amicus Therapeutics, Sanofi Genzyme and Takeda-Shire. JJR has received honoraria for lectures and attending meetings and\/or travel from Amicus Therapeutics, Takeda and Sanofi Genzyme, and for advisory roles from Amicus Therapeutics and Sanofi Genzyme. JRG has participated in advisory boards of Amicus Therapeutics and Sanofi Genzyme. AH is a study coordinator for clinical trials sponsored by Sanofi Genzyme and has received honoraria for presentations and advisory roles from Amicus Therapeutics, Sanofi Genzyme, Chiesi Global Rare Diseases and Takeda-Shire. AM has received honoraria for advisory roles from Alnylam, Amicus Therapeutics, Sanofi Genzyme, and Takeda-Shire. JMGP has received honoraria for advisory roles from Sanofi Genzyme and Takeda-Shire, and for lectures from Takeda-Shire, Amicus Therapeutics. EF has received honoraria for lectures from Takeda and attending meetings from Amicus Therapuetics. AAB is an employee of and holds stock in Amicus Therapeutics. RT has received honoraria for presentations and advisory roles from Amicus Therapeutics, Takeda, Sanofi and Chiesi. MARZ, and JVT have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"8"}}